Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating prostate cancer with Anti-prostate specific membrane antigen antibodies

a prostate cancer and specific membrane technology, applied in the field of prostate cancer treatment with anti-prostate specific membrane antigen antibodies, can solve the problems of limited systemic therapy, poor treatment effect of cytotoxic chemotherapy, and very limited treatment of prostate cancer, and achieve the effect of improving the modalities of preventing and treating

Inactive Publication Date: 2009-11-12
CORNELL RES FOUNDATION INC
View PDF75 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The modified antibodies provide a targeted approach to prostate cancer treatment, potentially offering improved survival benefits and treatment efficacy by specifically binding to PSMA-expressing cells, facilitating delivery of therapeutic agents and promoting apoptosis.

Problems solved by technology

There is currently very limited treatment for prostate cancer once it has metastasized (spread beyond the prostate).
Currently, systemic therapy is limited to various forms of androgen (male hormone) deprivation.
Cytotoxic chemotherapy is poorly tolerated in this age group and generally considered ineffective and / or impractical.
Thus, chemotherapeutic regimen has not demonstrated a significant survival benefit in this patient group.
Historically, the drawback of this procedure is that most cancers had spread beyond the bounds of the operation by the time they were detected.
Patients with bulky, high-grade tumors are less likely to be successfully treated by radical prostatectomy.
Diethylstilbestrol from estrogen is another useful hormonal therapy which has a disadvantage of causing cardiovascular toxicity.
As a result, it blocks the effect of testostcronc, increasing serum testosterone concentrations and allows patients to remain potent—a significant problem after radical prostatectomy and radiation treatments.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating prostate cancer with Anti-prostate specific membrane antigen antibodies
  • Methods of treating prostate cancer with Anti-prostate specific membrane antigen antibodies
  • Methods of treating prostate cancer with Anti-prostate specific membrane antigen antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Chelation of Anti-PSMA Antibodies To 111Indium, 90Yttrium, and 177Lutetium

[0447]The modified anti-PSMA monoclonal antibodies can be radiolabeled with 111Indium, 90Yttrium, or 177Lutetium by directly coupling one of the four carboxylic acid groups of the chelator 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) to primary amines present on the surface of the antibodies. The DOTA conjugated antibody is then purified, sterile filtered, and vialed. Prior to use, the purified antibodies can be mixed with the desired radiolabel which binds to DOTA.

Chelation Process

[0448]Monoclonal antibody deJ591 was conjugated with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) and subsequently radiolabeled with 111In, 90Y and 177Lu. Radiolabeling and quality control tests were performed on three separate vials of clinical grade mAb deJ591.

[0449]All reagents used in the conjugation and purification of deJ591 were made from pyrogen-free water. In the specific case of ...

example 2

Pharmacokinetics and Biodistribution of 131I- and 111In-Labeled deJ591 and Murine J415 in Nude Mice Bearing LNCaP Human Prostate Tumors

[0483]In nude mice bearing PSMA-positive human LNCaP tumors, the pharmacokinetics, biodistribution and tumor uptake of monoclonal deJ591 and murine J415 antibodies radiolabeled with 131I or 111In was analyzed. Autoradiographic studies were performed to identify intra-tumoral distribution of radiolabeled MAbs.

[0484]deJ591 and J415 were labeled with 131I using the iodogen method (see Franker and Speck (1978), Biochem Biophys Res Commun 80:849-57) to a specific activity of 400 MBq / mg (21, 23). For 111In labeling, the J415 and deJ591 antibodies were first conjugated with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) and then labeled with 111In to produce specific activities of 200 MBq / mg.

[0485]Prostate carcinoma cell lines LNCaP, DU145 and PC3 (American Type Culture Collection, Rockville, Md.) were grown in RPMI 1640, supplemented wi...

example 3

Animal Studies Using 90Y-DOTA-deJ591

[0496]In in vitro and in vivo animal models, 90Y-DOTA-deJ591 has demonstrated substantial anti-tumor activity. In these studies, immunodeficient ‘nude’ mice were implanted intramuscularly with PSMA-expressing human prostate cancer cells (LNCaP). In some studies, the same animals were simultaneously implanted in the opposite thigh with a PSMA-absent human prostate cancer line (PC3). Cancers were allowed to ‘establish’ for a period of approximately 2 weeks during which time the cancer develops a blood supply allowing further growth. At the time of treatment initiation, the cancer implants average 1.0 cm in diameter (or approximately 5% of the animal's body weight).

[0497]Four groups of mice received a single injection of 1.3, 3.7, 5.55 or 7.4 MBq of 90Y-DOTA-deJ591. At a 1.3 MBq dose level, there was a mixed response with minimal reduction in tumor growth rate. However, at doses between 3.7-7.4 MBq, a clear anti-tumor dose-response relationship was o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Description

RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 10 / 379,838, filed Mar. 3, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10 / 160,505, filed May 30, 2002, which claims priority to U.S. provisional application Nos. 60 / 295,214 filed on Jun. 1, 2001, 60 / 323,585 filed on Sep. 20, 2001, and 60 / 362,810 filed on Mar. 8, 2002, the contents of all of which are incorporated herein by reference.[0002]This invention was made with government support under Department of Defense Grant number DAMD17-98-1-8594. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention relates to antibodies, e.g., modified, e.g., deimmunized, antibodies, to the extracellular domain of human prostate specific membrane antigen (PSMA) and their uses in treating, preventing, and diagnosing prostatic disorders and cancers.BACKGROUND OF THE INVENTION[0004]Prostate cancer is one of the most common cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00A61KA61K47/48A61K51/10C07K16/30
CPCA61K51/1072A61K2039/505A61K2039/545C07K16/3069C07K2317/24C07K2317/56A61K47/6851A61K47/6869A61P35/00A61K45/06A61K51/1045C07K16/30C07K2317/14
Inventor BANDER, NEIL H.
Owner CORNELL RES FOUNDATION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com